ConnectM Reports 9% Revenue Growth to $8.9 Million, 139% Growth in Core Businesses and 28% Improvement in Operating Loss for Third Quarter 2026

ConnectM Technology Solutions, Inc. (CNTM) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ConnectM Reports 9% Revenue Growth to $8.9 Million, 139% Growth in Core Businesses and 28% Improvement in Operating Loss for Third Quarter 2026 MARLBOROUGH, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- ConnectM Technology Solutions, Inc. (OTCQX: CNTM) (“ConnectM” or the

Event · Earnings
Original reporting
Published Nov 17, 2026, 2:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CNTM
Bullish
medium confidence
Mentioned
$CNTM
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CNTMBullishMed
01

Why it matters

The filing updates traders on continuing-operations performance, segment contribution shifts, cost reductions, and liquidity/cash burn, all of which can affect near-term positioning in small-cap energy infrastructure and AI-adjacent infrastructure names.

02

Market read

Fresh quarterly numbers show improving operating loss and core segment growth post-restructuring, but losses and cash used in operations persist.

03

What to watch

Non-cash charges tied to financial instruments and the company’s share of losses of Sun Solar LLC may overstate underlying operating momentum; also, the India divestiture timing complicates year-over-year comparability.

Relevance 7/10Novelty 7/10Timing: today’s SEC 8-K furnished results for Q3 2026

Background

ConnectM’s Q3 2026 is the first full quarter after its June 17, 2026 divestiture of India operations, with revenue now generated in the US.

Company-level read

Ticker impact

$CNTMBullishMedium confidence
Context

ConnectM reports Q3 2026 revenue from continuing operations up 9% to $8.9M and operating loss improved 28% to $1.8M after its June 2026 India divestiture.

Expected impact

Likely modest upward bias as investors price in operating-loss improvement and core revenue growth, tempered by continued net loss and operating cash outflow.

Evidence & confidence

The filing provides fresh quarterly datapoints (revenue, segment mix, SG&A, operating loss, cash used) tied to the post-divestiture structure, but the company remains loss-making and cash-negative.

Market effects

Signals demand and monetization progress in AI energy infrastructure themes (power, thermal, intelligence), though impact is company-specific and OTC-scale.

Primarily US revenue exposure after divesting India operations, reducing cross-region earnings uncertainty.

Limited direct global read-through given the company’s small scale and OTC listing.

Counterpoint

The headline revenue growth may be driven by portfolio simplification and segment reclassification, while net loss and operating cash burn remain substantial.

Key entities

  • ConnectM Technology Solutions, Inc.

    OTCQX-listed company reporting Q3 2026 results on continuing operations after divesting India.

  • Keen Labs

    Segment generating $7.5M (84% of revenue) in Q3 2026, up 139% year-over-year.

  • Sun Solar LLC

    Company reports a share of losses included in net loss from continuing operations.

  • Blue Cloud Softech Solutions Limited

    Received shares in the India divestiture; shares are subject to a lock-up expiring February 2027.

Related articles

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.

$RIMEMed

Algorhythm Holdings Reports Third Quarter 2026 Financial Results

Algorhythm Holdings, Inc. (RIME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Algorhythm Holdings Reports Third Quarter 2026 Financial Results Company Completes Azure Energy Acquisition and Begins Strategic Restructuring Fort Lauderdale, FL, November 17, 2026 – Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME ), a diversified holding co

$PULMMed

Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger Merger with Eos SENOLYTIX expected to close by end of the year Framingham, Mass., November 17, 2026 – Pulmatrix, Inc. (“Pulmatrix”, the “Company” or “our”) (Nasdaq: PULM), a biopharmaceut